Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 222 articles: HTML format

Single Articles

October 2025
1. TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
   Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
   J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   
2. THEVENOT T, Desmarets M, Tio G
   Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?
   J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
3. GARG P, Verma N, Jalan R
   Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
   J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
4. RUDLER M
   Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial.
   J Hepatol. 2025 Oct 6:S0168-8278(25)02476-6. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
5. OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
   Cause-specific mortality in patients with steatotic liver disease in the United States.
   J Hepatol. 2025;83:860-869.
   PubMed     Abstract available
   
   
   
6. DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
   High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
   J Hepatol. 2025;83:849-859.
   PubMed     Abstract available
   
   
   September 2025
7. LISMAN T, Puente A, Garcia-Pagan JC
   Anticoagulant therapy to delay disease progression in patients with cirrhosis - reponse to Acka et al., Bot et al. and Feng et al.
   J Hepatol. 2025 Sep 25:S0168-8278(25)02495-X. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
8. VERMA N, Kaur P, Garg P, Ranjan V, et al
   Corrigendum to "Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis" [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028].
   J Hepatol. 2025 Sep 25:S0168-8278(25)02475-4. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
9. ZHANG T
   RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
   J Hepatol. 2025 Sep 24:S0168-8278(25)02499-7. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
10. AKCA M, Ketenci YB, Demiroz H, Avcioglu U, et al
    Concerns on Rivaroxaban Use in Cirrhosis: Pharmacokinetic, Safety, and Bleeding Risk Considerations.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02489-4. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
11. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].
    J Hepatol. 2025 Sep 5:S0168-8278(25)02439-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
12. NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
    The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
    J Hepatol. 2025;83:790-799.
    PubMed     Abstract available
    
    
    August 2025
13. VERMA N, Kaur P, Jalan R
    Disease Staging and Clinical State in Cirrhosis: Is severity, acuity and pathophysiology the missing link?
    J Hepatol. 2025 Aug 25:S0168-8278(25)02456-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
14. ROMERO-CRISTOBAL M
    Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
15. RIDOLA L, Riggio O
    Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
16. VERMA N, Garg P, Kaur P, Munjal S, et al
    Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis.
    J Hepatol. 2025 Aug 12:S0168-8278(25)02405-5. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
17. PIANO S, Patidar KR, Juanola A
    Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02395-5. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
18. BJORN AB, Jensen MD, Pero A, Villadsen GE, et al
    Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02390-6. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
19. HARRISON SA, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, et al
    A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
    J Hepatol. 2025;83:293-303.
    PubMed     Abstract available
    
    
    
20. STURM L, Schultheiss M, Stohr F, Labenz C, et al
    Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS.
    J Hepatol. 2025;83:348-357.
    PubMed     Abstract available
    
    
    
21. YIP TC, Lee HW, Lin H, Tsochatzis E, et al
    Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;83:304-314.
    PubMed     Abstract available
    
    
    
22. VERMA N, Angeli P, Jalan R
    Stratification, Therapeutic Targeting and Towards Personalised Care in Cirrhosis.
    J Hepatol. 2025 Aug 1:S0168-8278(25)02378-5. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    July 2025
23. RUDLER M
    Simvastatin and rifaximin in patients with decompensated cirrhosis: Still a place for LIVER HOPE?
    J Hepatol. 2025 Jul 30:S0168-8278(25)02323-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
24. PUENTE A, Turon F, Martinez J, Fortea JI, et al
    Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.
    J Hepatol. 2025 Jul 19:S0168-8278(25)02336-0. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
25. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
26. THEVENOT T, Elkrief L, Bureau C, Bardou-Jacquet E, et al
    Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial.
    J Hepatol. 2025 Jul 11:S0168-8278(25)02318-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
27. 
    EASL Clinical Practice Guidelines on TIPS.
    J Hepatol. 2025;83:177-210.
    PubMed     Abstract available
    
    
    
28. DE ZAWADZKI A, Leeming DJ, Sanyal AJ, Anstee QM, et al
    Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.
    J Hepatol. 2025;83:239-257.
    PubMed     Abstract available
    
    
    
29. POSE E, Piano S, Thiele M, Fabrellas N, et al
    Moving diagnosis of liver fibrosis into the community.
    J Hepatol. 2025;83:258-270.
    PubMed     Abstract available
    
    
    
30. WALLACE C, Gamkrelidze I, Estes C, Razavi H, et al
    Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.
    J Hepatol. 2025;83:21-30.
    PubMed     Abstract available
    
    
    
31. ALLEN AM, Kamath PS
    Staging decompensated cirrhosis: Lumping, splitting, or just rearranging the deck chairs on the Titanic?
    J Hepatol. 2025 Jul 1:S0168-8278(25)02198-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    May 2025
32. RUDLER M
    Autologous macrophage therapy for compensated cirrhosis, some hope at the horizon.
    J Hepatol. 2025 May 23:S0168-8278(25)00248-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
33. 
    EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
34. 
    EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease.
    J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
35. CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
    Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis.
    J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
36. CALES P, Canivet CM, Costentin C, Lannes A, et al
    A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
    J Hepatol. 2025;82:794-804.
    PubMed     Abstract available
    
    
    
37. ABDURRACHIM D, Lek S, Ong CZL, Wong CK, et al
    Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
    J Hepatol. 2025;82:898-908.
    PubMed     Abstract available
    
    
    April 2025
38. REIBERGER T, Maasoumy B
    Advancing our understanding of recompensated cirrhosis - the new "holy grail" of decompensated cirrhosis.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00241-7. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
39. TONON M, Gagliardi R, Pompili E, Barone A, et al
    Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00245-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
40. NAIK I, Yeo YH, Ng WH, Sheng-Kai Ma K, et al
    Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis.
    J Hepatol. 2025 Apr 11:S0168-8278(25)00232-6. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
41. SUN SS, Zhang J, Jin YP, Li L, et al
    A Rare Cause of Lipid Metabolism Disorder and Cirrhosis in an Adult.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00227-2. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    March 2025
42. SCHLEICHER EM, Karbannek H, Weinmann-Menke J, Galle PR, et al
    Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury.
    J Hepatol. 2025 Mar 19:S0168-8278(25)00164-3. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
43. LANTINGA MA, Tapper EB, Drenth JPH
    Reply: Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Mar 12:S0168-8278(25)00161-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
44. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Clinical and Pathophysiological Characteristics of Non-acute Decompensation of Cirrhosis.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00137-0. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
45. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
46. TELLEZ L, Rincon D, Payance A, Jaillais A, et al
    Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.
    J Hepatol. 2025;82:480-489.
    PubMed     Abstract available
    
    
    
47. ZHONG Q, Zhou R, Huang YN, Huang RD, et al
    Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.
    J Hepatol. 2025;82:427-437.
    PubMed     Abstract available
    
    
    February 2025
48. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
49. LOHSE AW, Kamath PS, Sarin SK
    The complexity of portal hypertension without (apparent) cirrhosis.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00088-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
50. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
    Response to: "Procedural bleeding in patients with cirrhosis: from prediction towards prevention".
    J Hepatol. 2025 Feb 19:S0168-8278(25)00087-X. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
51. MA AT, Juanola A, Sole C, Gines P, et al
    Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00086-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
52. MARTI-AGUADO D, Calleja JL, Bataller R, Crespo J, et al
    Reply to: "The HDL criterion for MetALD can misclassify patients with cirrhosis".
    J Hepatol. 2025 Feb 4:S0168-8278(25)00057-1. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
53. XUE X, Liu R, Cai Y, Gong L, et al
    Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available
    
    
    
54. MARKOVIC J, Li R, Khanal R, Peng Q, et al
    Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis.
    J Hepatol. 2025;82:301-314.
    PubMed     Abstract available
    
    
    
55. LIU YJ, Kimura M, Li X, Sulc J, et al
    ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
    J Hepatol. 2025;82:174-188.
    PubMed     Abstract available
    
    
    January 2025
56. LISMAN T
    Procedural bleeding in patients with cirrhosis: from prediction towards prevention.
    J Hepatol. 2025 Jan 11:S0168-8278(25)00010-8. doi: 10.1016/j.jhep.2025.
    PubMed    
    
    
    
57. RUDLER M
    Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?
    J Hepatol. 2025 Jan 11:S0168-8278(24)02773-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
58. GENG A, Brenig RG, Roux J, Lutge M, et al
    Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges.
    J Hepatol. 2025 Jan 10:S0168-8278(24)02818-6. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
59. BAJAJ JS, Fagan A, Gavis EA, Sterling RK, et al
    Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
    J Hepatol. 2025 Jan 10:S0168-8278(25)00005-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
60. DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
    Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
    J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
61. CROUCHET E, Dachraoui M, Juhling F, Roehlen N, et al
    Targeting the liver clock improves fibrosis by restoring TGF-beta signaling.
    J Hepatol. 2025;82:120-133.
    PubMed     Abstract available
    
    
    
62. KRENDL FJ, Cardini B, Zoller H, Schneeberger S, et al
    Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers.
    J Hepatol. 2025;82:e12-e14.
    PubMed    
    
    
    December 2024
63. IM GY, Bibireddy A, Rath S
    The HDL criterion for MetALD can misclassify patients with cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02781-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
64. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02772-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
65. ENGELMANN C
    Rifaximin in cirrhosis: Is its microbiological spotless record under threat?
    J Hepatol. 2024 Dec 16:S0168-8278(24)02735-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
66. ZANETTO A, Campello E, Bulato C, Willems R, et al
    Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
    J Hepatol. 2024 Dec 11:S0168-8278(24)02762-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
67. MARTI-AGUADO D, Calleja JL, Vilar-Gomez E, Iruzubieta P, et al
    Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;81:930-940.
    PubMed     Abstract available
    
    
    November 2024
68. CHE-TO LAI J, Wong GL, Tse YK, Hui VW, et al
    Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02718-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
69. VANDERSCHUEREN E, Wim Laleman
    Non-invasive algorithms could outperform HVPG in selecting candidates for non-selective beta-blockers in cirrhosis.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02711-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
70. HUR MH, Lee JH
    Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
71. KIM HY, Rosenthal SB, Liu X, Miciano C, et al
    Multi-Modal Analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Hepatol. 2024 Nov 8:S0168-8278(24)02667-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
72. HARRISON SA, Dubourg J
    Liver biopsy evaluation in MASH drug development: Think thrice, act wise.
    J Hepatol. 2024;81:886-894.
    PubMed     Abstract available
    
    
    
73. OH JH, Ahn SB, Cho S, Nah EH, et al
    Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
    J Hepatol. 2024;81:772-780.
    PubMed     Abstract available
    
    
    October 2024
74. CAO Z, Yao Y, Cai M, Zhang C, et al
    Blood markers for type-1,-2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis.
    J Hepatol. 2024 Oct 25:S0168-8278(24)02649-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
75. NADIM MK, Kellum JA, Durand F
    Reply to correspondence on "Acute kidney Injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting".
    J Hepatol. 2024 Oct 23:S0168-8278(24)02646-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
76. LEE S, Arefaine B, Begum N, Stamouli M, et al
    Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial.
    J Hepatol. 2024 Oct 22:S0168-8278(24)02635-7. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
77. TALANIAN M, Almeqdadi M, Chen HH
    From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
    J Hepatol. 2024;81:e147-e150.
    PubMed    
    
    
    
78. TONON M, Barone A, Calvino V, Santori V, et al
    Reply to: correspondance on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e170-e171.
    PubMed    
    
    
    
79. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
    Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    J Hepatol. 2024;81:590-599.
    PubMed     Abstract available
    
    
    
80. YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
    Assessment of fatigue and its impact in chronic liver disease.
    J Hepatol. 2024;81:726-742.
    PubMed     Abstract available
    
    
    September 2024
81. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
82. XIAO G, Ren H
    A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
    J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
83. DAJTI E, Villanueva C, Berzigotti A, Brujats A, et al
    Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial.
    J Hepatol. 2024 Sep 18:S0168-8278(24)02553-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    August 2024
84. TORRES S, El Maimouni C, Herrera G, Fernandez J, et al
    SPONTANEOUS CANDIDEMIA, A REAL INFECTION IN ADVANCED CIRRHOSIS.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02499-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
85. LV Y, Wang Q, Luo B, Bai W, et al
    Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02485-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
86. RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
    Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
    J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
87. YAO X, Song H, Shu H, Song J, et al
    Asymptomatic cirrhosis in a 35-year-old female.
    J Hepatol. 2024;81:e65-e67.
    PubMed    
    
    
    
88. TONON M, Barone A, Angeli P
    Reply to: Correspondence on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e74-e75.
    PubMed    
    
    
    
89. CASTERA L, Garteiser P, Laouenan C, Vidal-Trecan T, et al
    Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    J Hepatol. 2024;81:195-206.
    PubMed     Abstract available
    
    
    
90. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    PubMed     Abstract available
    
    
    July 2024
91. TONON M, Barone A, Angeli P
    Reply to: Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 Jul 29:S0168-8278(24)02434-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
92. DI COLA S, D'Amico G, Merli M
    Reply to "Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations ".
    J Hepatol. 2024 Jul 11:S0168-8278(24)02353-5. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
93. HE S, Luo Y, Ma W, Wang X, et al
    Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis.
    J Hepatol. 2024;81:135-148.
    PubMed     Abstract available
    
    
    June 2024
94. MENDOZA YP, Tsouka S, Semmler G, Seubnooch P, et al
    Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.
    J Hepatol. 2024 Jun 27:S0168-8278(24)02334-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
95. ROONEY M, Duduskar SN, Ghait M, Reissing J, et al
    Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection.
    J Hepatol. 2024 Jun 25:S0168-8278(24)02325-0. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
96. TARU V, Szabo G, Mehal W, Reiberger T, et al
    Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation.
    J Hepatol. 2024 Jun 20:S0168-8278(24)02322-5. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
97. SHAN D, Zhang G, Du Z
    Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
    J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
98. LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
    Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
    J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
99. DAI H, Zhu C, Huai Q, Xu W, et al
    Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
    J Hepatol. 2024;80:913-927.
    PubMed     Abstract available
    
    
    
100. WU XN, Wang MZ, Zhang N, Zhang W, et al
     Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
     J Hepatol. 2024;80:928-940.
     PubMed     Abstract available
     
     
     
101. XU M, Warner C, Duan X, Cheng Z, et al
     HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1alpha- and TGF-beta1-dependent pathway.
     J Hepatol. 2024;80:868-881.
     PubMed     Abstract available
     
     
     May 2024
102. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
     EASL position paper on clinical follow-up after HCV cure.
     J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
103. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
     Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
     J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
104. ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
     Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
     J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
105. DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
     Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
     J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
106. YANG M, Zhang F, Liu K
     Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
     J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
107. ZHANG Y, Xiao F, Xie R
     Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
     J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
108. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
     Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
     J Hepatol. 2024;80:730-743.
     PubMed     Abstract available
     
     
     
109. XIAO H, Niu D, Zhang B
     Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
     J Hepatol. 2024;80:e207-e209.
     PubMed    
     
     
     April 2024
110. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
     Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
     J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
111. MCGETTIGAN B, Shah V
     EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
     J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
112. CHEN VL, Du X, Oliveri A, Chen Y, et al
     Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
     J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
113. KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al
     Inequities in primary liver cancer in Europe: The state of play.
     J Hepatol. 2024;80:645-660.
     PubMed     Abstract available
     
     
     March 2024
114. D'AMICO G, Perricone G
     Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
     J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
115. NADIM MK, Kellum JA, Forni L, Francoz C, et al
     Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
     J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
116. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
     Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
     J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
117. YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
     Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
     J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
118. MA AT, Sole C, Juanola A, Escude L, et al
     Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
     J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
119. JACHS M, Sandmann L, Hartl L, Tergast T, et al
     Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
     J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
120. GE X, Desert R, Magdaleno F, Han H, et al
     Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
     J Hepatol. 2024;80:482-494.
     PubMed     Abstract available
     
     
     
121. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
     Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
     J Hepatol. 2024;80:467-481.
     PubMed     Abstract available
     
     
     
122. LARRUE H, Bureau C, D'Amico G
     Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
     J Hepatol. 2024;80:e109-e110.
     PubMed    
     
     
     February 2024
123. CAON E, Martins M, Hodgetts H, Blanken L, et al
     Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
     J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
124. ARTRU F, Reiberger T
     One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
     J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
125. HUANG CH, Tsai MH, Lin CY
     Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
     J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
126. WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
     Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
     J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
     PubMed     Abstract available
     
     
     
127. SILVA H, King JJ, Thorburn D, Luong TV, et al
     A rare cause of liver fibrosis in an adult patient.
     J Hepatol. 2024;80:e48-e50.
     PubMed    
     
     
     
128. LUO N, Zhang X, Huang J, Chen H, et al
     Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
     J Hepatol. 2024;80:e70-e71.
     PubMed    
     
     
     January 2024
129. NING Z
     An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
     J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
130. CAMPION D, Caviglia GP, Alessandria C
     Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
     J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
131. FAN X, Yang F, Zhou L, Yang L, et al
     Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
     J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
132. TANG R, Li Y, Chen R, Ma X, et al
     Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
     J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
     PubMed    
     
     
     
133. NAKANO M, Kawaguchi M, Kawaguchi T
     Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
     J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
134. JACHS M, Hartl L, Simbrunner B, Semmler G, et al
     Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
     J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
135. TERGAST TL, Maasoumy B
     The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
     J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
136. BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
     Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
     J Hepatol. 2024;80:73-81.
     PubMed     Abstract available
     
     
     December 2023
137. TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
     A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
     J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
138. VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
     Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
     J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
139. NARDELLI S, Riggio O, Marra F, Gioia S, et al
     Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
     J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
140. RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
     NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
     J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
141. ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
     A rare cause of painful hepatomegaly.
     J Hepatol. 2023;79:e228-e230.
     PubMed    
     
     
     
142. SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
     Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
     J Hepatol. 2023;79:1366-1373.
     PubMed     Abstract available
     
     
     November 2023
143. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
     ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
     J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     October 2023
144. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
     Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
     J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
145. FERNANDEZ-GARZA LE
     5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
     J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
146. CAMPION D, Ponzo P, Risso A, Caropreso P, et al
     A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
     J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
147. MURRAY SM, Pose E, Wittner M, Londono MC, et al
     Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
     J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
148. MAIWALL R, Rao Pasupuleti SS, Sarin SK
     AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
     J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
149. CHEN X, Pan J, Zhu Y
     Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
     J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
150. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
     Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
     J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
151. ABERG F, Savikko J, Eerola V, Nordin A, et al
     High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
     J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
152. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
     Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
     J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     September 2023
153. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
     The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
     J Hepatol. 2023;79:717-727.
     PubMed     Abstract available
     
     
     
154. BOURSIER J, Roux M, Sanyal AJ
     Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
     J Hepatol. 2023;79:e128-e129.
     PubMed    
     
     
     
155. HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
     NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
     J Hepatol. 2023;79:758-767.
     PubMed     Abstract available
     
     
     
156. WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
     Changing epidemiology, global trends and implications for outcomes of NAFLD.
     J Hepatol. 2023;79:842-852.
     PubMed     Abstract available
     
     
     
157. LIANG JX, Ampuero J, Niu H, Imajo K, et al
     An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
     J Hepatol. 2023;79:592-604.
     PubMed     Abstract available
     
     
     
158. SHARMA N, Pandey S, Yadav M, Mathew B, et al
     Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
     J Hepatol. 2023;79:677-691.
     PubMed     Abstract available
     
     
     
159. PERON JM, Larrue H, Izopet J, Buti M, et al
     The pressing need for a global HEV vaccine.
     J Hepatol. 2023;79:876-880.
     PubMed     Abstract available
     
     
     
160. NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
     Agile scores are a good predictor of liver-related events in patients with NAFLD.
     J Hepatol. 2023;79:e126-e127.
     PubMed    
     
     
     August 2023
161. EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
     Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
     J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
162. BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
     Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
     J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
163. 
     EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
     J Hepatol. 2023;79:461-491.
     PubMed     Abstract available
     
     
     
164. TSOCHATZIS EA
     Screening for liver fibrosis - sequential non-invasive testing works best.
     J Hepatol. 2023;79:263-265.
     PubMed    
     
     
     
165. KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
     Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
     J Hepatol. 2023;79:296-313.
     PubMed     Abstract available
     
     
     
166. KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
     Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
     J Hepatol. 2023;79:277-286.
     PubMed     Abstract available
     
     
     
167. TACKE F, Puengel T, Loomba R, Friedman SL, et al
     An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
     J Hepatol. 2023;79:552-566.
     PubMed     Abstract available
     
     
     
168. DEVARBHAVI H, Asrani SK, Arab JP, Nartey YA, et al
     Global burden of liver disease: 2023 update.
     J Hepatol. 2023;79:516-537.
     PubMed     Abstract available
     
     
     July 2023
169. PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
     Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
     J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
170. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
     Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
     J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
171. TAPPER EB, Bajaj JS
     Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
     J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
172. VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
     5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
     J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
173. AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
     Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
     J Hepatol. 2023;79:79-92.
     PubMed     Abstract available
     
     
     
174. HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
     Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
     J Hepatol. 2023;79:150-166.
     PubMed     Abstract available
     
     
     
175. VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
     Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
     J Hepatol. 2023;79:e23-e24.
     PubMed    
     
     
     
176. SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
     Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
     J Hepatol. 2023;79:e27-e28.
     PubMed    
     
     
     
177. PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
     From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
     J Hepatol. 2023;79:e25-e27.
     PubMed    
     
     
     
178. RIDOLA L, Riggio O
     Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
     J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
179. LI Z, Hu Y, Zou B
     The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
     J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     June 2023
180. AGRAWAL D, Ariga KK
     Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
     J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
181. CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
     Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
     J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
182. NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
     Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
     J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
183. ZHANG X, Sharma P, Maschmeyer P, Hu Y, et al
     GARP on hepatic stellate cells is essential for the development of liver fibrosis.
     J Hepatol. 2023 Jun 20:S0168-8278(23)00422-1. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
184. TAVABIE O
     Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
     J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
185. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
     Natural history of NASH cirrhosis in liver transplant waitlist registrants.
     J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
186. ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
     Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
     J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
187. LIU X, Wen X, Lu F
     Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
     J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
188. SENZOLO M, Garcia-Pagan JC
     A major research gap: the use of anticoagulants in cirrhosis.
     J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
189. FAN R, Chen L, Zhao S, Yang H, et al
     Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
     J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
190. ALBILLOS A, Guerrero A, Tellez L
     Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
     J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
191. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
     Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
     J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
192. ARTRU F, Goldberg D, Kamath PS
     Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
     J Hepatol. 2023;78:1118-1123.
     PubMed     Abstract available
     
     
     
193. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
     Liver transplantation in the patient with physical frailty.
     J Hepatol. 2023;78:1105-1117.
     PubMed     Abstract available
     
     
     May 2023
194. INNES H, Nahon P
     Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
     J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
195. SHAWCROSS DL, Thabut D, Amodio P
     Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
     J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
196. LARRUE H, D'Amico G, Olivas P, Lv Y, et al
     TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
     J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
197. DI MARTINO V
     Methotrexate-induced liver fibrosis: The end of a long-held belief.
     J Hepatol. 2023;78:896-897.
     PubMed    
     
     
     
198. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
     Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
     J Hepatol. 2023;78:989-997.
     PubMed     Abstract available
     
     
     April 2023
199. MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
     A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
     J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
200. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
     Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
     J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
201. JIN K, Shi Y, Zhang H, Zhangyuan G, et al
     A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
     J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
202. VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
     Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
     J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     March 2023
203. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
     Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
     J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
204. LISMAN T, Bernal W, Luyendyk JP
     Anticoagulation to prevent disease progression in patients with cirrhosis.
     J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
205. BAWEJA S, Kumari A, Negi P, Tomar A, et al
     Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
     J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
206. MANGINI C, Gagliardi R, Causin F, Angeli P, et al
     Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
     J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
207. VIOLI F, Pignatelli P, Cammisotto V
     Platelet defetcts in cirrhosis: fact or fiction?
     J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
208. BANTEL H, Schulze-Osthoff K
     Non-invasive tests for evaluating treatment response in NAFLD.
     J Hepatol. 2023;78:e101-e102.
     PubMed    
     
     
     
209. DURAND F, Kellum JA, Nadim MK
     Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
     J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     February 2023
210. GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
     Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
     J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
     PubMed     Abstract available
     
     
     
211. SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
     International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
     J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     
212. ZENG L, Li X, Peng Z
     Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
     J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
     PubMed    
     
     
     January 2023
213. TAO L, Yang G, Sun T, Tao J, et al
     Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
     J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
     PubMed     Abstract available
     
     
     
214. ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
     A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
     J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
     PubMed     Abstract available
     
     
     December 2022
215. SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
     Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
     J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
     PubMed     Abstract available
     
     
     
216. YIP TC, Wong VW, Lai MS, Lai JC, et al
     Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
     J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
     PubMed     Abstract available
     
     
     November 2022
217. THABUT D, Kudo M
     Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
     J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
     PubMed     Abstract available
     
     
     
218. LUO L, Yao X, Yang W
     Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
     J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
     PubMed    
     
     
     
219. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
     Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
     J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
     PubMed    
     
     
     
220. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
     Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
     J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
     PubMed     Abstract available
     
     
     October 2022
221. PRYKE R, Guha IN
     Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
     J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
     PubMed     Abstract available
     
     
     September 2022
222. PATERNOSTRO R, Kwanten WJ, Reiberger T
     Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
     J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.